Setrobuvir

Setrobuvir^[1]
Names

IUPAC name N-(3-{(1R,2S,7R,8S)-3-[(4-fluorophenyl)methyl]-6-hydroxy-4-oxo-3-azatricyclo [6.2.1.02,7]undec-5-en-5-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7- yl)methanesulfonamide
Other names ANA-598; ANA598
Identifiers
CAS Registry Number	1214735-09-7^N 1071517-39-9^Y
ChEMBL	ChEMBL1076263^Y
ChemSpider	24680206^Y
InChI InChI=1S/C25H25FN4O6S2/c1-37(33,34)28-17-8-9-18-19(11-17)38(35,36)29-24(27-18)21-23(31)20-14-4-5-15(10-14)22(20)30(25(21)32)12-13-2-6-16(26)7-3-13/h2-3,6-9,11,14-15,20,22,28,31H,4-5,10,12H2,1H3,(H,27,29)/t14-,15+,20+,22-/m0/s1^Y Key: DEKOYVOWOVJMPM-RLHIPHHXSA-N^Y InChI=1/C25H25FN4O6S2/c1-37(33,34)28-17-8-9-18-19(11-17)38(35,36)29-24(27-18)21-23(31)20-14-4-5-15(10-14)22(20)30(25(21)32)12-13-2-6-16(26)7-3-13/h2-3,6-9,11,14-15,20,22,28,31H,4-5,10,12H2,1H3,(H,27,29)/t14-,15+,20+,22-/m0/s1 Key: DEKOYVOWOVJMPM-RLHIPHHXBY
Jmol-3D images	Image
KEGG	D10165^N
SMILES CS(NC(C=C1)=CC2=C1NC(C3=C(O)[C@@]4([H])[C@@]([C@@H]5CC[C@H]4C5)([H])N(CC6=CC=C(F)C=C6)C3=O)=NS2(=O)=O)(=O)=O
Properties
Molecular formula	C₂₅H₂₅FN₄O₆S₂
Molar mass	560.62 g·mol⁻¹
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
N verify (what is: Y/N?)
Infobox references

Setrobuvir (ANA-598) is an experimental drug candidate for the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir.^[2] It is currently in Phase IIb clinical trials, used in combination with interferon and ribavirin,^[3] targeting hepatitis C patients with genotype 1.^[2]

Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.^[4]

References

↑ Statement on a Nonproprietary Name Adopted by the USAN Council
↑ 2.0 2.1 "HCV Followup: Anadys Acquired for Active Antiviral". Central Science, Chemical & Engineering News. October 24, 2011.
↑ "Roche-Anadys Hookup Could Spark More Hep C Acquisitions". TheStreet.com. October 17, 2011.
↑ Ruebsam, F; Murphy, DE; Tran, CV; Li, LS; Zhao, J; Dragovich, PS; McGuire, HM; Xiang, AX et al. (2009). "Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase". Bioorganic & Medicinal Chemistry Letters 19 (22): 6404–12. doi:10.1016/j.bmcl.2009.09.045. PMID 19818610.